Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the genomics of Waldenström’s macroglobulinemia (WM), and highlights the importance of using novel therapeutic agents to target CXCR4 and MYD88 mutations. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.